"Rising Demand for Weight-Loss Drugs Drives Syringe-Filling Firms' Success"
Contract drug manufacturers are investing billions of dollars to expand or build factories that fill the injection pens used for weight-loss drugs like Novo Nordisk's Wegovy. The demand for fill-finish services is increasing as sales of weight-loss drugs, such as Wegovy and Eli Lilly's Mounjaro, soar. Pharmaceutical services companies are racing to secure more of this specialist work, with estimates suggesting that the market for GLP-1 agonists, including oral treatments, could be worth up to $100 billion within a decade. Companies like WuXi Biologics and Catalent are investing in pre-filled syringe capacity, while Novo and Lilly are also increasing their internal capacity. The fill-finish market is predicted to more than double by 2027, driven by the demand for weight-loss drugs and the development of biologic drugs.
